Table 2.
Comparison of Change in Blood Concentrations of Neuroendocrine Outcomes, From Baseline to Post-Drug Time-Pointa, Between Placebo and Ghrelin Sessions of the IV-ASA Experiment
| Placebo session, M (SEM) | Ghrelin session, M (SEM) | Independent samples t test | |
|---|---|---|---|
| Δ Leptin (Log10) concentration (pg/mL) | −0.11 (0.02) | −0.09 (0.02) | t (18) = −0.62, P = .54 |
| Δ GLP-1 (Log10) concentration (pg/mL) | −0.32 (0.04) | 0.16 (0.08) | t (20) = −4.91,P < .001 |
| Δ PP concentration (pg/mL) | −221.46 (28.44) | −43.87 (18.01) | t (20) = −5.27,P < .001 |
| Δ GIP concentration (pg/mL) | −151.94 (51.00) | −68.62 (79.23) | t (20) = −0.88,P = .38 |
| Δ Insulin concentration (pg/mL) | −81.95 (39.32) | −84.42 (144.79) | t (18) = 0.01,P = .98 |
| Δ IGF-1 concentration (ng/mL) | −4.63 (4.94) | 1.28 (4.19) | t (20) = −0.91,P = .37 |
| Δ Cortisol concentration (mcg/dL) | −3.15 (1.14) | 6.24 (1.70) | t (19) = −4.65,P < .001 |
| Δ Prolactin concentration (ng/mL) | −0.13 (0.78) | 12.74 (2.70) | t (18) = −4.56,P < .001 |
| Δ Aldosterone concentration (pg/mL) | −44.41 (18.31) | 18.07 (33.49) | t (19) = −1.67,P = .11 |
Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; IV-ASA, i.v. alcohol self-administration; M, mean; PP, pancreatic polypeptide; SEM, standard error of the mean.
a Baseline (T0): 25 minutes before the start of the ghrelin/placebo loading dose, post-drug (T1): 30 minutes after the start of the ghrelin/placebo continuous infusion. See Figure 1 for more details.